← Back to Screener
Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI)
Price$3.39
Favorite Metrics
Price vs S&P 500 (26W)-2.48%
Price vs S&P 500 (4W)4.27%
Market Capitalization$871.46M
All Metrics
P/CF (Annual)121.94x
Book Value / Share (Quarterly)$0.83
P/TBV (Annual)13.66x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-40.53%
Cash Flow / Share (Quarterly)$-0.28
Price vs S&P 500 (YTD)0.17%
Gross Margin (TTM)18.30%
Net Profit Margin (TTM)-70.41%
EPS (TTM)$-0.91
10-Day Avg Trading Volume2.01M
EPS Excl Extra (TTM)$-0.91
Revenue Growth (5Y)-8.15%
EPS (Annual)$-0.91
ROI (Annual)-24.43%
Gross Margin (Annual)18.30%
Net Profit Margin (5Y Avg)-23.96%
Cash / Share (Quarterly)$0.85
Revenue Growth QoQ (YoY)-11.59%
ROA (Last FY)-16.97%
Revenue Growth TTM (YoY)-28.34%
EBITD / Share (TTM)$-1.50
ROE (5Y Avg)-7.32%
Operating Margin (TTM)-115.89%
Cash Flow / Share (Annual)$-0.28
P/B Ratio4.10x
P/B Ratio (Quarterly)3.91x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)5.26x
Net Interest Coverage (TTM)-14.11x
ROA (TTM)-15.05%
EV / EBITDA (TTM)2.01x
EPS Incl Extra (Annual)$-0.91
Current Ratio (Annual)6.60x
Quick Ratio (Quarterly)5.40x
3-Month Avg Trading Volume1.45M
52-Week Price Return97.09%
EV / Free Cash Flow (Annual)3.16x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.24
P/S Ratio (Annual)4.69x
Asset Turnover (Annual)0.24x
52-Week High$4.11
Operating Margin (5Y Avg)-16.92%
EPS Excl Extra (Annual)$-0.91
CapEx CAGR (5Y)-12.34%
26-Week Price Return6.27%
Quick Ratio (Annual)5.40x
13-Week Price Return-13.96%
Total Debt / Equity (Annual)1.52x
Current Ratio (Quarterly)6.60x
Enterprise Value$977.446
Revenue / Share Growth (5Y)3.13%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)19.28%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)3.35x
Pretax Margin (Annual)-126.50%
Cash / Share (Annual)$0.85
3-Month Return Std Dev57.20%
Gross Margin (5Y Avg)54.38%
Net Income / Employee (TTM)$-0
ROE (Last FY)-61.58%
Net Interest Coverage (Annual)-14.11x
EPS Basic Excl Extra (Annual)$-0.91
P/FCF (TTM)76.27x
Receivables Turnover (TTM)5.80x
EV / Free Cash Flow (TTM)38.73x
Total Debt / Equity (Quarterly)1.52x
EPS Incl Extra (TTM)$-0.91
Receivables Turnover (Annual)5.80x
ROI (TTM)-22.51%
P/S Ratio (TTM)4.69x
Pretax Margin (5Y Avg)23.06%
Revenue / Share (Annual)$1.29
Tangible BV / Share (Annual)$0.24
Price vs S&P 500 (52W)62.00%
Year-to-Date Return4.31%
5-Day Price Return10.78%
EPS Normalized (Annual)$-0.91
ROA (5Y Avg)-4.04%
Net Profit Margin (Annual)-70.41%
Month-to-Date Return19.79%
Cash Flow / Share (TTM)$0.75
EBITD / Share (Annual)$-1.50
Operating Margin (Annual)-115.89%
LT Debt / Equity (Annual)1.35x
ROI (5Y Avg)-3.36%
LT Debt / Equity (Quarterly)1.35x
EPS Basic Excl Extra (TTM)$-0.91
P/TBV (Quarterly)13.66x
P/B Ratio (Annual)3.91x
Inventory Turnover (TTM)3.35x
Pretax Margin (TTM)-126.50%
Book Value / Share (Annual)$0.83
Price vs S&P 500 (13W)-16.82%
Beta0.51x
P/FCF (Annual)14.36x
Revenue / Share (TTM)$1.28
ROE (TTM)-51.07%
52-Week Low$1.67
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.82
3.82
3.82
3.82
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MRVIMaravai LifeSciences Holdings, Inc. Class A Common Stock | 4.69x | -28.34% | 18.30% | — | $3.39 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Maravai LifeSciences provides critical enabling technologies and services for pharmaceutical and biotechnology companies developing drugs, vaccines, and diagnostics. The company operates through two segments: TriLink, which supplies nucleic acid products including mRNA and oligonucleotides; and Cygnus, which provides biologics safety testing and quality assurance solutions. Its products serve customers throughout drug development, manufacturing, and quality assurance processes.